ClinicalTrials.gg

Program

selnoflast

Also written as “Selnoflast” and “RO7486967”.

Its studies are mostly in Atherosclerosis · Parkinson Disease, led by Hoffmann-La Roche.

Furthest: phase 2, since Feb 25, 20262 company-led studies, 1 open or runningNext primary completion: Jan 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche21 open or runningphase 2since Feb 25, 2026Jun 21, 2023Jan 31, 2028phase 2 · NCT07448038
  • Named in Hoffmann-La Roche’s own pipeline as RG6418 selnoflast, phase 2, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 21, 2023First study: phase 1 study in Parkinson DiseaseFirst studyNCT05924243 · 60 enrolled · United States, Netherlands, United Kingdom
  2. Feb 25, 2026Phase 2 study in AtherosclerosisPhase 2 reachedNCT07448038 · 162 planned · United States, Canada

Ahead

  1. Jan 31, 2028Primary completion: phase 2 study in AtherosclerosisNCT07448038

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07448038Atherosclerosis · United States, Canada2RecruitingJan 31, 2028162
NCT05924243Parkinson Disease · United States, Netherlands, United Kingdom1CompletedJul 18, 202460

How it is read

Names in the registry

  • “Selnoflast”, 1 entry
  • “RO7486967”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.